PRME News and Press, First Trust Heitman Global Prime Real Estate ETF From 01/02/24

CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime...

2023-12-22 23:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-12-19 10:30:00 ET Small-cap stocks are often attractive investments in bullish markets. While a bull market is not guaranteed in 2024, some small caps are already heating up in anticipation of better economic conditions next year. As a result, it might be a smart move to start adding s...

2023-12-01 14:45:50 ET Summary AI isn't just revolutionizing biotech; it's reinventing it. From predicting diseases to accelerating drug discovery, AI is turning data into medical gold, reshaping how we approach healthcare innovation. AI is turbocharging techniques like CRISPR and...

2023-11-30 07:45:00 ET Cathie Wood, founder and CEO of Ark Invest, has a unique approach to investing. She targets companies that are creating and applying disruptive technologies in fields such as artificial intelligence (AI), autonomous vehicles, genomics, and biotech. These companies hav...

Prime Medicine Inc. (PRME) is expected to report $-0.45 for Q3 2023

2023-11-03 17:37:01 ET Prime Medicine ( NASDAQ: PRME ) on Friday filed a prospectus for a mixed securities shelf offering of up to $500M. This prospectus is not an offer to sell these securities. SEC Filing For further details see: Prime Medicine files f...

2023-11-03 16:16:51 ET More on Prime Medicine Prime Medicine: Not Yet Primed For Retail Investment Gene editing stocks gain after Eli Lilly deal amid FDA AdCom Seeking Alpha’s Quant Rating on Prime Medicine Historical earnings data for Prime Medicine ...

-- Presented new preclinical research across multiple programs, including proof-of-concept data from in vivo rodent and large animal studies, as well as updates on proprietary delivery systems -- -- Shared detailed safety evaluation of lead Prime Editors across multiple programs; prel...

2023-11-03 15:23:43 ET More on XBI and IBB Biopharma Bounce-Back: From Policy Pains To Profitable Plains IBB: The Illness Of Idiosyncratic Risk Jefferies is bullish on XBI at around $70 for year-end and first quarter 2024 returns Citi turns cautious on pharma...